Small molecule inhibitors that are able to block entry, replication, or subsequent host immune responses induced by SARS-CoV-2 (2019-nCoV) are of great interest in investigating therapeutic strategies to treat and prevent Coronavirus Disease-2019 (COVID-19). InvivoGen offers a selection of inhibitors known to act at different stages of the infection.
SARS-CoV-2 fusion inhibitor
Coronaviruses, such as SARS-CoV and SARS-CoV-2, have the capacity to use fusion with the surface membrane of target cells in order to deliver their viral RNA genome into the cytoplasm. In the case of COVID-19, targeting the fusion machinery of SARS-CoV-2 is a promising therapeutic strategy.
Endosomal acidification inhibitors
Coronaviruses, such as SARS-CoV and presumably SARS-CoV-2, enter and are trafficked through the host cell in endosomes. Targeting and blocking endosomal acidification may help further study how SARS-CoV-2 infects host cells.
JAK/STAT signaling inhibitor
Activation of the JAK/STAT pathway by type I IFNs amplifies their action through the production of a plethora of IFN-stimulated genes. However, in the case of COVID‑19, this can lead to hyper-inflammation and ultimately to a cytokine storm. Inhibiting this pathway will help further investigations into the COVID‑19 associated cytokine storm.
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
InvivoGen's Reviews: Spotlight on COVID-19